Publication:
Perspectives for clinical use of engineered human host defense antimicrobial peptides.

Loading...
Thumbnail Image

Date

2017

Authors

Pachón-Ibáñez, María Eugenia
Smani, Younes
Pachón, Jerónimo
Sánchez-Céspedes, Javier

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Infectious diseases caused by bacteria, viruses or fungi are among the leading causes of death worldwide. The emergence of drug-resistance mechanisms, especially among bacteria, threatens the efficacy of all current antimicrobial agents, some of them already ineffective. As a result, there is an urgent need for new antimicrobial drugs. Host defense antimicrobial peptides (HDPs) are natural occurring and well-conserved peptides of innate immunity, broadly active against Gram-negative and Gram-positive bacteria, viruses and fungi. They also are able to exert immunomodulatory and adjuvant functions by acting as chemotactic for immune cells, and inducing cytokines and chemokines secretion. Moreover, they show low propensity to elicit microbial adaptation, probably because of their non-specific mechanism of action, and are able to neutralize exotoxins and endotoxins. HDPs have the potential to be a great source of novel antimicrobial agents. The goal of this review is to provide an overview of the advances made in the development of human defensins as well as the cathelicidin LL-37 and their derivatives as antimicrobial agents against bacteria, viruses and fungi for clinical use.

Description

MeSH Terms

Anti-Infective Agents
Antimicrobial Cationic Peptides
Bacteria
Bacterial Infections
Defensins
Endotoxins
Exotoxins
Fungi
Humans
Microbial Sensitivity Tests
Mycoses
Virus Diseases
Viruses
Cathelicidins

DeCS Terms

CIE Terms

Keywords

antibacterial, antifungal, antiviral, cathelicidin, defensins, infectious diseases

Citation